Naloxone reversal of morphine- and morphine-6-glucuronide-induced respiratory depression in healthy volunteers: a mechanism-based pharmacokinetic-pharmacodynamic modeling study
- PMID: 20461002
- DOI: 10.1097/ALN.0b013e3181d5e29d
Naloxone reversal of morphine- and morphine-6-glucuronide-induced respiratory depression in healthy volunteers: a mechanism-based pharmacokinetic-pharmacodynamic modeling study
Abstract
Background: Opioid-induced respiratory depression is antagonized effectively by the competitive opioid receptor antagonist naloxone. However, to fully understand the complex opioid agonist-antagonist interaction, the effects of various naloxone doses on morphine and morphine-6-glucuronide (M6G)-induced respiratory depression were studied in healthy volunteers.
Methods: Twenty-four subjects received 0.15 mg/kg morphine intravenously at t = 0 followed by placebo, 200 or 400 microg naloxone at t = 30 min. Thirty-two subjects received 0.3 mg/kg M6G intravenously at t = 0 followed by placebo, 25, 100, or 400 microg naloxone at t = 55 min. There were a total of 8 subjects per treatment group. Respiration was measured on a breath-to-breath basis at constant end-tidal Pco2. A mechanism-based pharmacokinetic-pharmacodynamic model consisting of a part describing biophase equilibration and a part describing receptor association-dissociation kinetics was used to analyze the data.
Results: Naloxone reversal of M6G-induced respiratory depression developed more slowly than reversal of the respiratory effect of morphine. A simulation study revealed that this was related to the slower receptor association-dissociation kinetics of M6G (koff M6G = 0.0327 +/- 0.00455 min versus morphine 0.138 +/- 0.0148 min; values are typical +/-SE). Duration of naloxone reversal was longer for M6G. This was related to the three- to fourfold greater potency of naloxone as an antagonist against M6G compared with morphine. Increasing the naloxone dose had no effect on the speed of reversal, but it did extend reversal duration.
Conclusions: Naloxone reversal of the opioid effect is dependent on the receptor association-dissociation kinetics of the opioid that needs reversal with respect to the rate of reversal. The pharmacodynamics of naloxone determines reversal magnitude and duration.
Similar articles
-
Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences.Anesthesiology. 2004 Jan;100(1):120-33. doi: 10.1097/00000542-200401000-00021. Anesthesiology. 2004. PMID: 14695733 Clinical Trial.
-
Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers.Clin Pharmacokinet. 2007;46(11):965-80. doi: 10.2165/00003088-200746110-00004. Clin Pharmacokinet. 2007. PMID: 17922561 Clinical Trial.
-
PBPK-PD model for predicting morphine pharmacokinetics, CNS effects and naloxone antagonism in humans.Acta Pharmacol Sin. 2024 Aug;45(8):1752-1764. doi: 10.1038/s41401-024-01255-2. Epub 2024 Apr 3. Acta Pharmacol Sin. 2024. PMID: 38570601 Free PMC article.
-
Non-analgesic effects of opioids: opioid-induced respiratory depression.Curr Pharm Des. 2012;18(37):5994-6004. doi: 10.2174/138161212803582469. Curr Pharm Des. 2012. PMID: 22747535 Review.
-
Morphine-6-glucuronide: actions and mechanisms.Med Res Rev. 2005 Sep;25(5):521-44. doi: 10.1002/med.20035. Med Res Rev. 2005. PMID: 15952175 Review.
Cited by
-
Mechanistic pharmacokinetic-pharmacodynamic modeling and simulations of naloxone auto-injector 10 mg reversal of opioid-induced respiratory depression.CPT Pharmacometrics Syst Pharmacol. 2024 Oct;13(10):1722-1733. doi: 10.1002/psp4.13215. Epub 2024 Sep 16. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 39283753 Free PMC article.
-
Tolerance to Opioid-Induced Respiratory Depression in Chronic High-Dose Opioid Users: A Model-Based Comparison With Opioid-Naïve Individuals.Clin Pharmacol Ther. 2021 Mar;109(3):637-645. doi: 10.1002/cpt.2027. Epub 2020 Oct 5. Clin Pharmacol Ther. 2021. PMID: 32865832 Free PMC article.
-
Molecular Pharmacology of δ-Opioid Receptors.Pharmacol Rev. 2016 Jul;68(3):631-700. doi: 10.1124/pr.114.008979. Pharmacol Rev. 2016. PMID: 27343248 Free PMC article. Review.
-
Treatment of opioid overdose: current approaches and recent advances.Psychopharmacology (Berl). 2022 Jul;239(7):2063-2081. doi: 10.1007/s00213-022-06125-5. Epub 2022 Apr 7. Psychopharmacology (Berl). 2022. PMID: 35385972 Free PMC article. Review.
-
Mechanism of opioid addiction and its intervention therapy: Focusing on the reward circuitry and mu-opioid receptor.MedComm (2020). 2022 Jun 22;3(3):e148. doi: 10.1002/mco2.148. eCollection 2022 Sep. MedComm (2020). 2022. PMID: 35774845 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical